EU Nephrologists Foresee Travere/CSL Vifor’s FILSPARITM (sparsentan) Transforming IgA Nephropathy Treatment as the First Non-Immunosuppressive Therapy
April 30, 2024 14:40 ET
|
Spherix Global Insights
EXTON, PA, April 30, 2024 (GLOBE NEWSWIRE) -- Over the past several years, glomerular diseases have garnered significant attention from the nephrology industry, largely driven by the persistent...
AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease
April 23, 2024 06:00 ET
|
Averoa
Grenoble, France, 23rd April 2024 - Averoa, a biopharmaceutical company bringing innovative therapeutic solutions to people with renal diseases, announces the submission of a marketing authorisation...
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
March 25, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Sequel’s twiist™ Automated Insulin Delivery System Receives FDA 510(k) Clearance
March 18, 2024 07:05 ET
|
Sequel Med Tech
Sequel’s twiist™ automated insulin delivery system receives FDA 510(k) clearance. Significant advancements for people with people with Type 1 diabetes.
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
March 14, 2024 15:11 ET
|
Spherix Global Insights
EXTON, PA, March 14, 2024 (GLOBE NEWSWIRE) -- The past several years have brought a transformative shift to the IgA nephropathy (IgAN) treatment landscape, including the introduction of two new...
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
March 13, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Promising Preclinical Results in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose Portion of Clinical Trial Complete – LOS ALTOS, Calif., March 13, 2024 ...
Dr. Lisandro Montalvo-Burke Joins Healthmap Solutions as Medical Director for Puerto Rico
February 13, 2024 08:00 ET
|
Healthmap Solutions
Healthmap Solutions, Inc. has named Lisandro Montalvo-Burke, MD as its new Medical Director in Puerto Rico.
Dialysis Market Surges Towards USD 198.2 Billion by 2033 | Driven by Rising Demand for Renal Replacement Therapy Solutions
February 06, 2024 04:42 ET
|
Market.Us
New York, Feb. 06, 2024 (GLOBE NEWSWIRE) -- According to Market.us, the Dialysis Market value is projected to exceed USD 198.2 Billion by 2033, with a projected CAGR of 5.5% from 2024 to 2033. The...
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
January 23, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Topline Data from OLC Pivotal Trial Expected in Q2 2024 –– OLC will target the multibillion-dollar hyperphosphatemia market – LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive...
Renal function test market forecasting a US$1.6 billion illumination by 2030, with Persistence Market Research
January 22, 2024 02:00 ET
|
Persistence Market Research
New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Renal Function Test Market: A Comprehensive Analysis Renal Function Tests are a series of diagnostic tests used to assess the functioning of the kidneys....